Rxcurve
HCPCS J9301 · per 10 MG

Obinutuzumab inj

Products billed under this code include Gazyva.

Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J9301

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Gazyva Genentech, Inc. 50242-0070-01 100 $8,503.90

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $85.039 +$0.576 10 MG Obinutuzumab inj v1, posted September 17, 2026
3Q26 $84.463 +$2.657 10 MG Obinutuzumab inj v1, posted September 15, 2026
2Q26 $81.806 +$0.181 10 MG Obinutuzumab inj v1, posted September 15, 2026
1Q26 $81.625 +$2.629 10 MG Obinutuzumab inj v1, posted September 15, 2026
4Q25 $78.996 +$0.535 10 MG Obinutuzumab inj v1, posted September 8, 2026
3Q25 $78.461 +$3.249 10 MG Obinutuzumab inj v1, posted March 10, 2026
2Q25 $75.212 +$0.385 10 MG Obinutuzumab inj v1, posted March 10, 2026
1Q25 $74.827 +$0.239 10 MG Obinutuzumab inj v1, posted December 19, 2025
4Q24 $74.588 +$0.438 10 MG Obinutuzumab inj v1, posted June 11, 2025
3Q24 $74.15 +$3.934 10 MG Obinutuzumab inj v1, posted June 11, 2025
2Q24 $70.216 −$0.126 10 MG Obinutuzumab inj v1, posted March 11, 2025
1Q24 $70.342 +$0.056 10 MG Obinutuzumab inj v1, posted December 19, 2024
4Q23 $70.286 −$0.26 10 MG Obinutuzumab inj v1, posted October 10, 2024
3Q23 $70.546 +$3.634 10 MG Obinutuzumab inj v1, posted June 5, 2024
2Q23 $66.912 −$0.036 10 MG Obinutuzumab inj v1, posted February 23, 2024
1Q23 $66.948 −$0.406 10 MG Obinutuzumab inj v1, posted December 6, 2023
4Q22 $67.354 +$1.349 10 MG Obinutuzumab inj v1, posted June 22, 2023
3Q22 $66.005 +$2.187 10 MG Obinutuzumab inj v1, posted June 9, 2023
2Q22 $63.818 −$0.29 10 MG Obinutuzumab inj v1, posted December 14, 2022
1Q22 $64.108 −$0.428 10 MG Obinutuzumab inj v1, posted June 8, 2022
4Q21 $64.536 +$0.12 10 MG Obinutuzumab inj v1, posted June 2, 2022
3Q21 $64.416 +$1.332 10 MG Obinutuzumab inj v1, posted June 2, 2022
2Q21 $63.084 −$0.459 10 MG Obinutuzumab inj v1, posted March 1, 2022
1Q21 $63.543 – 10 MG Obinutuzumab inj v1, posted December 10, 2021

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files